Prevalence of ESR1 mutations in cell-free DNA and outcomes in metastatic breast cancer: a secondary analysis of the BOLERO-2 clinical trial
S Chandarlapaty, D Chen, W He, P Sung… - JAMA …, 2016 - jamanetwork.com
Importance Estrogen receptor α (ESR1) mutations found in metastatic breast cancer (MBC)
promote ligand-independent receptor activation and resistance to estrogen-deprivation
therapy in laboratory models. The prevalence of these mutations and their potential impact
on clinical outcomes has not been established. Objective To determine the prevalence
ofESR1mutations (Y537S and D538G) in estrogen receptor (ER)-positive MBC and
determine whether mutation is associated with inferior outcomes. Design, Setting, and …
promote ligand-independent receptor activation and resistance to estrogen-deprivation
therapy in laboratory models. The prevalence of these mutations and their potential impact
on clinical outcomes has not been established. Objective To determine the prevalence
ofESR1mutations (Y537S and D538G) in estrogen receptor (ER)-positive MBC and
determine whether mutation is associated with inferior outcomes. Design, Setting, and …
